Literature DB >> 18491128

Subconjunctival antisense oligonucleotides targeting TNF-alpha influence immunopathology and viral replication in murine HSV-1 retinitis.

Jin Li1, Susanne Wasmuth, Dirk Bauer, Hanna Baehler, Maren Hennig, Arnd Heiligenhaus.   

Abstract

BACKGROUND: To investigate the role of tumor necrosis factor-alpha (TNF-alpha) in immunopathology and viral replication in the contralateral eye in the von Szily model of herpes simplex virus (HSV)-1 acute retinitis.
METHODS: In vivo distribution was analyzed after subconjunctival injection of FITC-labeled antisense oligonucleotides (ASON). After HSV-1 (KOS) was injected in the right anterior chamber (AC) in BALB/c mice, the course of the contralateral retinitis was evaluated. The left eyes were treated with either TNF-alpha ASON, sequence-unspecific control (CON), or buffer. The ocular TNF-alpha content was quantified by ELISA. The delayed-type hypersensitivity (DTH) reaction, uptake of [3H]thymidine from regional lymph nodes (rln)- and spleen cells, serum-neutralizing antibodies, and viral titer in the eyes were evaluated.
RESULTS: After subconjunctival injection, FITC-labeled ASON were found in the choroid and retina. In the TNF-alpha ASON-treated eyes, TNF-alpha expression and the incidence and severity of retinitis were reduced on day 8 postinfection (PI) (p < 0.05). On day 10 PI, higher viral titers were only seen in the eyes of the TNF-alpha ASON group (p < 0.05), and retinitis was slightly more severe on day 12 PI. While the HSV-1 specific [3H]thymidine uptake from rln cells was higher in the TNF-alpha ASON mice (p < 0.05), the [3H]thymidine uptake from spleen cells, the DTH response, and the neutralizing-antibody titers did not differ between the groups.
CONCLUSIONS: After regional blockade of TNF-alpha in experimental HSV-1 retinitis TNF-alpha seems to possess an antiviral capacity against HSV-1 in the contralateral eye and participates in the immunopathology of HSV-1-induced acute retinitis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18491128     DOI: 10.1007/s00417-008-0839-y

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  46 in total

1.  An antisense oligodeoxynucleotide against vascular endothelial growth factor in a nonhuman primate model of iris neovascularization.

Authors:  Robert B Bhisitkul; Gregory S Robinson; Rachel S Moulton; Kevin P Claffey; Evangelos S Gragoudas; Joan W Miller
Journal:  Arch Ophthalmol       Date:  2005-02

2.  Intraocular distribution of 70-kDa dextran after subconjunctival injection in mice.

Authors:  Tae Woo Kim; James D Lindsey; Makoto Aihara; Todd L Anthony; Robert N Weinreb
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-06       Impact factor: 4.799

3.  Antiviral effects of recombinant tumour necrosis factor in vitro.

Authors:  J Mestan; W Digel; S Mittnacht; H Hillen; D Blohm; A Möller; H Jacobsen; H Kirchner
Journal:  Nature       Date:  1986 Oct 30-Nov 5       Impact factor: 49.962

4.  CD4+ T-cell type 1 and type 2 cytokines in the HSV-1 infected cornea.

Authors:  A Heiligenhaus; D Bauer; M Zheng; S Mrzyk; K P Steuhl
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1999-05       Impact factor: 3.117

Review 5.  Acute retinal necrosis: insights into pathogenesis from the mouse model.

Authors:  S S Atherton
Journal:  Herpes       Date:  2001-11

6.  New indications for treatment of chronic inflammation by TNF-alpha blockade.

Authors:  Andreas M Reimold
Journal:  Am J Med Sci       Date:  2003-02       Impact factor: 2.378

7.  T cells in the uninjected eye after anterior chamber inoculation of herpes simplex virus type 1.

Authors:  A Azumi; S S Atherton
Journal:  Invest Ophthalmol Vis Sci       Date:  1998-01       Impact factor: 4.799

8.  Herpes simplex virus type 1 alters transcript levels of tumor necrosis factor-alpha and interleukin-6 in retinal glial cells.

Authors:  K M Drescher; J A Whittum-Hudson
Journal:  Invest Ophthalmol Vis Sci       Date:  1996-10       Impact factor: 4.799

Review 9.  The future role of anti-tumour necrosis factor-alpha products in the treatment of Crohn's disease.

Authors:  R A van Hogezand; H W Verspaget
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

10.  Suppression of herpes simplex virus type 1 (HSV-1)-induced pneumonia in mice by inhibition of inducible nitric oxide synthase (iNOS, NOS2).

Authors:  H Adler; J L Beland; N C Del-Pan; L Kobzik; J P Brewer; T R Martin; I J Rimm
Journal:  J Exp Med       Date:  1997-05-05       Impact factor: 14.307

View more
  2 in total

1.  Intravitreal treatment with antisense oligonucleotides targeting tumor necrosis factor-α in murine herpes simplex virus type 1 retinitis.

Authors:  Rafael S Grajewski; Jin Li; Susanne Wasmuth; Maren Hennig; Dirk Bauer; Arnd Heiligenhaus
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-11-10       Impact factor: 3.117

2.  A Therapeutic Antiviral Antibody Inhibits the Anterograde Directed Neuron-to-Cell Spread of Herpes Simplex Virus and Protects against Ocular Disease.

Authors:  Dirk Bauer; Mira Alt; Miriam Dirks; Anna Buch; Christiane S Heilingloh; Ulf Dittmer; Bernd Giebel; André Görgens; Vivien Palapys; Maren Kasper; Anna M Eis-Hübinger; Beate Sodeik; Arnd Heiligenhaus; Michael Roggendorf; Adalbert Krawczyk
Journal:  Front Microbiol       Date:  2017-10-31       Impact factor: 5.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.